Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Dermatol Clin. 2011 Jan;29(1):1-8. doi: 10.1016/j.det.2010.09.006.

    Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection.

    Source

    Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. douglas.walsh@afrims.org

    Abstract

    Buruli ulcer (BU), caused by the environmental organism Mycobacterium ulcerans and characterized by necrotizing skin and bone lesions, poses important public health issues as the third most common mycobacterial infection in humans. Pathogenesis of M ulcerans is mediated by mycolactone, a necrotizing immunosuppressive toxin. First-line therapy for BU is rifampin plus streptomycin, sometimes with surgery. New insights into the pathogenesis of BU should improve control strategies.

    Published by Elsevier Inc.

    PMID:
    21095521
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk